Englewood Lab (A950140) Q4 2025 earnings summary

Executive summary

• Revenue grew 14.1% year-over-year to USD 152.4 million, with operating income up 90.7% to USD 26.3 million and net income up 21.2% to USD 17.4 million.

• Strong growth was driven by increased orders from US indie brands and expansion of OTC product lines.

• Financial stability maintained with a debt ratio of 37.9% and equity ratio of 72.5%.

Financial highlights

• Current assets increased 23.0% to USD 122.8 million, mainly from higher receivables and cash.

• Operating cash flow rose 64.8% to USD 15.6 million; year-end cash and equivalents reached USD 25.1 million.

• Gross margin improved to 27.7% from 21.2% year-over-year.

• Earnings per share (basic) were USD 0.88, up from USD 0.72 in the prior year.

Outlook and guidance

• The global cosmetics OEM/ODM market is projected to grow from USD 73.3 billion in 2025 to USD 77.4 billion in 2026.

• The company plans to enhance production efficiency and invest in automation to strengthen competitiveness.

• Focus remains on expanding premium skincare and OTC product offerings for global clients.